These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31454413)

  • 1. Δ
    Xi ZX; Muldoon P; Wang XF; Bi GH; Damaj MI; Lichtman AH; Pertwee RG; Gardner EL
    Br J Pharmacol; 2019 Dec; 176(24):4773-4784. PubMed ID: 31454413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats.
    Forget B; Guranda M; Gamaleddin I; Goldberg SR; Le Foll B
    Psychopharmacology (Berl); 2016 May; 233(10):1823-8. PubMed ID: 26864774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking.
    Gamaleddin I; Zvonok A; Makriyannis A; Goldberg SR; Le Foll B
    PLoS One; 2012; 7(1):e29900. PubMed ID: 22291896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
    Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.
    Gamaleddin I; Wertheim C; Zhu AZ; Coen KM; Vemuri K; Makryannis A; Goldberg SR; Le Foll B
    Addict Biol; 2012 Jan; 17(1):47-61. PubMed ID: 21521420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarities and differences upon binding of naturally occurring Δ
    Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
    Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pure Δ
    Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
    Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice.
    Ignatowska-Jankowska BM; Muldoon PP; Lichtman AH; Damaj MI
    Psychopharmacology (Berl); 2013 Oct; 229(4):591-601. PubMed ID: 23652588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
    Bolognini D; Costa B; Maione S; Comelli F; Marini P; Di Marzo V; Parolaro D; Ross RA; Gauson LA; Cascio MG; Pertwee RG
    Br J Pharmacol; 2010 Jun; 160(3):677-87. PubMed ID: 20590571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
    Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
    Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
    McPartland JM; Duncan M; Di Marzo V; Pertwee RG
    Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats.
    Adamczyk P; Miszkiel J; McCreary AC; Filip M; Papp M; Przegaliński E
    Brain Res; 2012 Mar; 1444():45-54. PubMed ID: 22325096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endogenous cannabinoid system modulates nicotine reward and dependence.
    Merritt LL; Martin BR; Walters C; Lichtman AH; Damaj MI
    J Pharmacol Exp Ther; 2008 Aug; 326(2):483-92. PubMed ID: 18451315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
    Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.
    Bátkai S; Mukhopadhyay P; Horváth B; Rajesh M; Gao RY; Mahadevan A; Amere M; Battista N; Lichtman AH; Gauson LA; Maccarrone M; Pertwee RG; Pacher P
    Br J Pharmacol; 2012 Apr; 165(8):2450-61. PubMed ID: 21470208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
    García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
    Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.